Related Experiment Videos
Tumor-targeted Salmonella. Highly selective delivery vectors
1Vion Pharmaceuticals, Inc., New Haven Connecticut 06511, USA. DBermude@Vionpharm.com
Abstract:
Genetically engineered Salmonella offer an intriguing new approach to selectively target solid tumors, including melanoma, lung, colon, breast, kidney and liver. These bacteria target tumors after systemic administration and selectively replicate within them. Specificity for tumors is often more than 1,000 times greater than for any other tissue. Auxotrophic mutations make these bacteria highly safe and form the basis for maintaining tumor specificity. An altered lipid greatly reduces the potential for septic shock yet also retains the antitumor properties of these bacteria. These bacteria have innate antitumor activity towards both primary and metastatic tumors and the ability to deliver proteins capable of activating chemotherapeutic agents directly within tumors. The delay in tumor growth results in mice that survive up to twice as long. These bacteria are susceptible to a wide range of antibiotics, allowing external control of the vector after administration. The combination of these features within a single vector seems specially surprising considering their unlikely source.
Insights
Genetically engineered Salmonella selectively target and replicate within solid tumors, offering a novel cancer therapy. These modified bacteria exhibit enhanced safety and significant antitumor activity, prolonging survival in preclinical models.
Area of Science:
- Oncology
- Microbiology
- Genetic Engineering
Background:
- Solid tumors present a significant challenge in cancer treatment.
- Developing targeted therapies with reduced systemic toxicity is crucial.
- Genetically modified bacteria offer a potential platform for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of genetically engineered Salmonella for targeting solid tumors.
- To assess the bacteria's tumor specificity, replication capabilities, and antitumor effects.
- To investigate the potential of these bacteria as a drug delivery system for cancer therapy.
Main Methods:
- Systemic administration of genetically engineered Salmonella in preclinical tumor models.
- Assessment of bacterial tumor targeting and replication specificity.
- Evaluation of innate antitumor activity and potential for activating chemotherapeutic agents.
- Analysis of safety profiles, including septic shock potential and antibiotic susceptibility.
Main Results:
- Engineered Salmonella demonstrated high specificity (>1,000-fold) for tumors over other tissues.
- Auxotrophic mutations and altered lipids enhanced safety while retaining antitumor properties.
- Significant delay in tumor growth was observed, extending survival in mice up to twofold.
- Bacteria showed innate antitumor activity against primary and metastatic tumors and could deliver therapeutic proteins.
Conclusions:
- Genetically engineered Salmonella represent a promising, safe, and effective strategy for targeting and treating solid tumors.
- These bacteria possess inherent antitumor capabilities and can be utilized for targeted drug delivery.
- The ability to control the bacterial vector with antibiotics provides an additional safety mechanism.